Login to Your Account

HDAC Inhibitors are Promising Targets in Drug Development

By Peter Winter

Tuesday, September 4, 2012

Since the beginning of the year a significant amount of research data has been reported on histone deacetylases (HDACs), the cellular enzymes whose functions include turning gene expression off and on. They are considered to be among the most promising targets in drug development for cancer therapy. New HDAC inhibitors are emerging and are actively being tested in the clinic.

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription